tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Mar 24;9(4):307.
doi: 10.3390/vaccines9040307.
Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates
Yong Bok Seo[SUP] 1 [/SUP], You Suk Suh[SUP] 2 [/SUP], Ji In Ryu[SUP] 1 [/SUP], Hwanhee Jang[SUP] 1 [/SUP], Hanseul Oh[SUP] 3 [/SUP], Bon-Sang Koo[SUP] 3 [/SUP], Sang-Hwan Seo[SUP] 4 [/SUP], Jung Joo Hong[SUP] 3 [/SUP], Manki Song[SUP] 4 [/SUP], Sung-Joo Kim[SUP] 5 [/SUP], Young Chul Sung[SUP] 1 2 [/SUP]
Affiliations
Abstract
The unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 elicited not only S-specific systemic and pulmonary antibody responses but also Th1-biased T cell responses in a dose-dependent manner. GX-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses. Notably, when the immunized nonhuman primates were challenged at 10 weeks after the last vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a control. These findings indicate that GX-19 vaccination provides a durable protective immune response and also support further development of GX-19 as a vaccine candidate for SARS-CoV-2.
Keywords: COVID-19; DNA vaccine.
. 2021 Mar 24;9(4):307.
doi: 10.3390/vaccines9040307.
Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates
Yong Bok Seo[SUP] 1 [/SUP], You Suk Suh[SUP] 2 [/SUP], Ji In Ryu[SUP] 1 [/SUP], Hwanhee Jang[SUP] 1 [/SUP], Hanseul Oh[SUP] 3 [/SUP], Bon-Sang Koo[SUP] 3 [/SUP], Sang-Hwan Seo[SUP] 4 [/SUP], Jung Joo Hong[SUP] 3 [/SUP], Manki Song[SUP] 4 [/SUP], Sung-Joo Kim[SUP] 5 [/SUP], Young Chul Sung[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33804981
- DOI: 10.3390/vaccines9040307
Abstract
The unprecedented and rapid spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) has motivated the need for a rapidly producible and scalable vaccine. Here, we developed a synthetic soluble SARS-CoV-2 spike (S) DNA-based vaccine candidate, GX-19. In mice, immunization with GX-19 elicited not only S-specific systemic and pulmonary antibody responses but also Th1-biased T cell responses in a dose-dependent manner. GX-19-vaccinated nonhuman primates seroconverted rapidly and exhibited a detectable neutralizing antibody response as well as multifunctional CD4+ and CD8+ T cell responses. Notably, when the immunized nonhuman primates were challenged at 10 weeks after the last vaccination with GX-19, they had reduced viral loads in contrast to non-vaccinated primates as a control. These findings indicate that GX-19 vaccination provides a durable protective immune response and also support further development of GX-19 as a vaccine candidate for SARS-CoV-2.
Keywords: COVID-19; DNA vaccine.